Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 8 to 10 amino acid residues in defined sequence
Reexamination Certificate
2006-09-08
2010-11-16
Lukton, David (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
8 to 10 amino acid residues in defined sequence
C514S002600, C530S326000, C530S327000, C530S329000, C530S330000, C530S345000
Reexamination Certificate
active
07834144
ABSTRACT:
The invention relates to peptoid reagents that interact preferentially with a pathogenic form of a conformational disease protein as compared to a nonpathogenic form of the conformational disease protein where the peptoid reagent comprises an amino-terminal region, a carboxy-terminal region, and at least one peptoid region between the amino-terminal region and the carboxy-terminal region where the peptoid region comprises 3 to about 30 N-substituted glycines, and optionally one or more amino acids. The invention also relates to methods of using the peptoids in detecting and isolating prions, and in the treatment and prevention of prion-related diseases.
REFERENCES:
patent: 5422425 (1995-06-01), Kriegler et al.
patent: 6075121 (2000-06-01), Simon et al.
patent: 6211149 (2001-04-01), Chesebro et al.
patent: 6251433 (2001-06-01), Zuckermann et al.
patent: 6372214 (2002-04-01), Prusiner et al.
patent: 6462171 (2002-10-01), Soto-Jara et al.
patent: 6656716 (2003-12-01), Plowman et al.
patent: 6680170 (2004-01-01), Plowman et al.
patent: 6765088 (2004-07-01), Korth et al.
patent: 6787319 (2004-09-01), Ozenberger et al.
patent: 7005295 (2006-02-01), Ozenberger et al.
patent: 7097997 (2006-08-01), Deslys et al.
patent: 7101973 (2006-09-01), Ozenberger et al.
patent: 7166471 (2007-01-01), Orser et al.
patent: 7435540 (2008-10-01), Cashman et al.
patent: 7479482 (2009-01-01), Frangione et al.
patent: 7482172 (2009-01-01), Zheng
patent: 2003/0040468 (2003-02-01), Barron et al.
patent: 2003/0092613 (2003-05-01), Lee et al.
patent: 2003/0215880 (2003-11-01), Burton et al.
patent: 2004/0009167 (2004-01-01), Rider
patent: 2004/0052928 (2004-03-01), Gazit
patent: 2004/0072236 (2004-04-01), Cashman et al.
patent: 2004/0186273 (2004-09-01), Hammond et al.
patent: 2004/0208919 (2004-10-01), Nicolau et al.
patent: 2004/0229280 (2004-11-01), Hammond et al.
patent: 2005/0014196 (2005-01-01), Carbonell et al.
patent: 2005/0026165 (2005-02-01), Orser et al.
patent: 2005/0100962 (2005-05-01), van Oers et al.
patent: 2005/0118645 (2005-06-01), Michelitsch et al.
patent: 2006/0035242 (2006-02-01), Michelitsch et al.
patent: 2006/0057671 (2006-03-01), Orser et al.
patent: 2006/0094071 (2006-05-01), Engenann et al.
patent: 2006/0235199 (2006-10-01), Mihara et al.
patent: 2006/0248605 (2006-11-01), Ozenberger et al.
patent: 2006/0275910 (2006-12-01), Orser et al.
patent: 2006/0286672 (2006-12-01), Orser et al.
patent: 2007/0093415 (2007-04-01), Martin
patent: 2008/0171341 (2008-07-01), Orser et al.
patent: 2009/0099343 (2009-04-01), Peretz et al.
patent: 2009/0130774 (2009-05-01), Peretz et al.
patent: 19741607 (1999-03-01), None
patent: 0909388 (1999-04-01), None
patent: 1382971 (2004-01-01), None
patent: 1457500 (2004-09-01), None
patent: 1643252 (2006-04-01), None
patent: WO-93/11155 (1993-06-01), None
patent: WO-93/23432 (1993-11-01), None
patent: WO94/06451 (1994-03-01), None
patent: WO-94/06451 (1994-03-01), None
patent: WO-97/16728 (1997-05-01), None
patent: WO-99/15651 (1999-04-01), None
patent: WO-00/29849 (2000-05-01), None
patent: WO-00/43791 (2000-07-01), None
patent: WO-00/78344 (2000-12-01), None
patent: WO-01/07479 (2001-02-01), None
patent: WO-01/23425 (2001-04-01), None
patent: WO-01/35104 (2001-05-01), None
patent: WO-01/77687 (2001-10-01), None
patent: WO-01/97785 (2001-12-01), None
patent: WO-02/04954 (2002-01-01), None
patent: WO-02/14351 (2002-02-01), None
patent: WO-02/052046 (2002-07-01), None
patent: WO02052046 (2002-07-01), None
patent: WO-02/065134 (2002-08-01), None
patent: WO-02/097444 (2002-12-01), None
patent: WO-03/045128 (2003-06-01), None
patent: WO-03/050139 (2003-06-01), None
patent: WO 03/073106 (2003-09-01), None
patent: WO-03/085086 (2003-10-01), None
patent: WO-2004/005920 (2004-01-01), None
patent: WO-2004/018511 (2004-03-01), None
patent: WO-2004/029072 (2004-04-01), None
patent: WO-2004/037854 (2004-05-01), None
patent: WO-2004/046728 (2004-06-01), None
patent: WO-2004/050851 (2004-06-01), None
patent: WO-2004/090102 (2004-10-01), None
patent: WO-2004/091523 (2004-10-01), None
patent: WO-2004/092197 (2004-10-01), None
patent: WO-2005/016127 (2005-02-01), None
patent: WO-2005/016957 (2005-02-01), None
patent: WO2005016127 (2005-02-01), None
patent: WO-2005/057166 (2005-06-01), None
patent: WO-2005/060697 (2005-07-01), None
patent: WO2005060697 (2005-07-01), None
patent: WO-2005/075507 (2005-08-01), None
patent: WO-2006/026977 (2006-03-01), None
patent: WO 2006/076687 (2006-07-01), None
patent: WO-2006/087550 (2006-08-01), None
patent: WO-2006/088823 (2006-08-01), None
patent: WO-2007/030804 (2007-03-01), None
patent: WO-2007/145589 (2007-12-01), None
patent: WO-2008/013859 (2008-01-01), None
patent: WO-2008/134034 (2008-11-01), None
Alluri (J Am Chem Soc 125, 13995-14004 2003).
Wender (Proc Natl Acad Sci 97(24), 13003-13008, 2000).
Kodadek, Thomas (Molecular BioSystems 2(1), 25-35, 2006).
Reddy et al., “Transformation of Low-Affinity Lead Compounds into High-Affinity Protein Capture Agents”, Chemistry & Biology, vol. 11(8), pp. 1127-1137.
Firer, M A. (Oct. 30, 2001). “Efficient elution of functional proteins in affinity chromatography,”Journal Of Biochemical And Biophysical Methods49:433-442.
Fischer, M. B. et al. (Nov. 23, 2000). “Binding of disease-associated prion protein to plasminogen,”Nature408(6811):479-483.
Gasset, M. et al. (1992). “Predicted .alpha.-Helical Regions of the Prion Protein When Synthesized as Peptides Form Amyloid,”Proc. Natl. Acad. Sci. USA89:10940-10944.
Gasset, M. et al. (1993). “Perturbation of the secondary structure of the scrapie prion protein under conditions that alter infectivity,”Proc. Natl. Acad. Sci. USA90(1):1-5.
Gauczynski, E. et al. (2001). “Interaction of Prion Proteins With Cell Surface Receptors, Molecular Chaperones, and Other Molecules,”Advances In Protein Chemistry57:229-272.
Georgieva, (2002). “Prion diseases. Antibody-mediated prion prevention,”Experimental Pathology and Parasitologyp. 60-63.
Gorske et al. (Apr. 14, 2005). “Expedient synthesis and design strategies for new peptoid construction,”Organic Letters 7(8):1521-1524.
Haynes et al. (Jul. 4, 2005). “Comblike, monodisperse polypeptoid drag-tags for DNA separations by end-labeled free-solution elecrtophoresis (ELPSE),”Bioconjugate Chemistry16(4):929-938.
Huang et al. (Jun. 1998). “Lipitoids—novel cationic lipids for cellular delivery of plasmid DNA in vitro,”Chemistry and Biology5(6):345-354.
Ingrosso, L. et al. (Jun. 2002). “Molecular Diagnostics of Transmissible Spongiform Encephalopathies,”Trends in Molecular Medicine8(6):273-280.
International Search Report and Written Opinion mailed Aug. 5, 2009, for PCT Application No. PCT/US2009/042185 filed on Apr. 29, 2009, 15 pages.
International Search Report mailed Feb. 13, 2007, for PCT Application No. PCT/US2006/035226 filed Sep. 8, 2006, 1 page.
International Search Report mailed Jan. 8, 2007, for PCT Application No. PCT/US2006/001433 filed Jan. 13, 2006, 1 page.
International Search Report mailed Oct. 3, 2007, for PCT Application No. PCT/US2006/001437 filed Jan. 13, 2006, 2 pages.
International Search Report mailed Sep. 24, 2007, for PCT Application No. PCT/US2006/001090 filed Jan. 13, 2006, 2 pages.
Irani et al. (2003). “Diagnosis and prevention of bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease,”Annual Review of Medicine54:305-319.
Ironside, J. W. et al. (2002). “Pathological Diagnosis of Variant Creutzfeldt-Jakob Disease,”APMIS110:79-87.
Kirshenbaum et al. (Apr. 14, 1998). “Sequence-specific polypeptoids: A diverse family of heteropolymers with stable secondary structure,”Proc. Natl. Acad. Sci. USA95(8):4303-4308.
Koller et al. (2002). “Induction of antibodies against murine full-length prion protein in wild-type mice,”Journal of Neuroimmunology132:113-116.
Lau, A L et al. (Jul. 10, 2007). “Characterization of prion protein (PrP)-derived peptides that discriminate
Connolly Michael D.
Gao Man
Peretz David
Shimizu Robert M.
Timoteo Gulliver
Hong Mei
Lukton David
Novartis AG
Tsao Patricia
LandOfFree
Prion-specific peptoid reagents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prion-specific peptoid reagents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prion-specific peptoid reagents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4241267